Drug and Therapeutics Bulletin 1997;35:1-4; doi:10.1136/dtb.1997.3511
Copyright © 1997 by the BMJ Publishing Group Ltd.

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Using ß2-stimulants in asthma

Relevant BNF section: 3.1.1

ß₂-selective adrenoceptor agonists (ß₂-stimulants) have been used for 30 years for the relief of symptoms in patients with all grades of asthma. They can also be used before activities likely to precipitate airway narrowing and are sometimes taken as regular treatment by patients with chronic asthma. The first ß₂-stimulants to be introduced were shorter-acting drugs such as salbutamol and terbutaline. The longer-acting ß₂-stimulants, salmeterol and eformoterol were developed more recently and their role in treating asthma is not yet fully defined. In this article we review the current place of ß₂-stimulants in asthma management.

This article has been cited by other articles:

				E. D. Bateman, S. S. Hurd, P. J. Barnes, J. Bousquet, J. M. Drazen, M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S. E. Pedersen, et al. Global strategy for asthma management and prevention: GINA executive summary Eur. Respir. J., January 1, 2008; 31(1): 143 - 178. [Abstract] [Full Text] [PDF]